First-Line Treatment of HER2-Positive Metastatic Breast Cancer With Dual Blockade Including Biosimilar Trastuzumab (SB3): Population-Based Real-World Data From the DBCG.

Celik, Alan; Berg, Tobias; Nielsen, Lise Birk; Jensen, Maj-Britt; Ejlertsen, Bent; Knoop, Ann; Andersson, Michael

Celik, Alan; Berg, Tobias; Nielsen, Lise Birk; Jensen, Maj-Britt; Ejlertsen, Bent; Knoop, Ann; Andersson, Michael.

Affiliation

Celik A; Danish Breast Cancer Group, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
Berg T; Danish Breast Cancer Group, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
Nielsen LB; Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
Jensen MB; Danish Breast Cancer Group, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
Ejlertsen B; Danish Breast Cancer Group, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
Knoop A; Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
Andersson M; Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.

Breast Cancer (Auckl) ; 16: 11782234221086992, 2022.

Article de En | MEDLINE | ID: mdl-35359608

Mots clés

Trastuzumab; biosimilar pharmaceuticals; breast

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Type d'étude: Observational_studies Langue: En Journal: Breast Cancer (Auckl) Année: 2022 Type de document: Article Pays d'affiliation: Danemark

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google